Cargando…
Secukinumab for rheumatology: development and its potential place in therapy
Rheumatic disease is not a single disorder, but a group of more than 100 diseases that affect joints, connective tissues, and/or internal organs. Although rheumatic diseases like rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis (AS) differ in their pathogenesis and clinical...
Autores principales: | Koenders, Marije I, van den Berg, Wim B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928657/ https://www.ncbi.nlm.nih.gov/pubmed/27445458 http://dx.doi.org/10.2147/DDDT.S105263 |
Ejemplares similares
-
The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models
por: Lubberts, Erik, et al.
Publicado: (2005) -
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
por: Schulze-Koops, Hendrik, et al.
Publicado: (2017) -
Plitidepsin: design, development, and potential place in therapy
por: Alonso-Álvarez, Sara, et al.
Publicado: (2017) -
Delafloxacin: design, development and potential place in therapy
por: Candel, Francisco Javier, et al.
Publicado: (2017) -
Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)